Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OPGNNASDAQ:PIIINASDAQ:PMDNASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOPGNOpGen$4.90-0.8%$4.64$0.53▼$5.25$49.33M-1.689,502 shs747 shsPIIIP3 Health Partners$6.47-3.1%$8.06$4.78▼$33.32$46.51M0.8420,209 shs2,076 shsPMDPsychemedics$2.67$2.52$1.63▼$3.25$16.31MN/A31,876 shs113,627 shsSERASera Prognostics$1.78+4.1%$2.47$1.37▼$9.13$67.06M0.71152,761 shs104,495 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOPGNOpGen0.00%+5.11%+0.82%+182.29%+97.60%PIIIP3 Health Partners0.00%-2.73%-19.41%-24.82%-79.36%PMDPsychemedics0.00%0.00%0.00%0.00%+18.67%SERASera Prognostics0.00%+10.32%-25.97%-58.70%-78.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners2.4625 of 5 stars3.34.00.00.02.50.80.6PMDPsychemedicsN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.5066 of 5 stars0.02.00.00.01.02.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.25154.74% UpsidePMDPsychemedics 0.00N/AN/AN/ASERASera Prognostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMD, SERA, PIII, and OPGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOPGNOpGen$2.67M18.61N/AN/A($11.55) per share-0.43PIIIP3 Health Partners$1.49B0.03$2.75 per share2.32$0.45 per share14.18PMDPsychemedics$22.10M0.74N/AN/A$1.15 per share2.32SERASera Prognostics$115K574.92N/AN/A$2.21 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$47.28N/AN/AN/A-6.95%-71.31%-11.93%8/6/2025 (Estimated)PMDPsychemedics-$4.15M-$0.51N/A∞N/A-14.59%-49.05%-27.26%N/ASERASera Prognostics-$36.24M-$0.94N/AN/AN/AN/A-51.73%-36.94%8/6/2025 (Estimated)Latest PMD, SERA, PIII, and OPGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PIIIP3 Health Partners-$5.00-$6.28-$1.28-$6.28$362.09 million$373.23 million5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 million3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 million3/19/2025Q4 2024SERASera Prognostics-$0.23-$0.25-$0.02-$0.25$0.01 million$0.02 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/APMDPsychemedicsN/AN/AN/AN/A1 YearsSERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53PMDPsychemedics0.011.591.59SERASera PrognosticsN/A2.112.11Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOPGNOpGen2.68%PIIIP3 Health Partners7.75%PMDPsychemedics32.07%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipOPGNOpGen43.80%PIIIP3 Health Partners17.79%PMDPsychemedics13.96%SERASera Prognostics13.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOPGNOpGen10010.07 million4.70 millionNot OptionablePIIIP3 Health Partners5007.19 million294.74 millionNot OptionablePMDPsychemedics1406.11 million5.26 millionNot OptionableSERASera Prognostics12037.67 million28.44 millionOptionablePMD, SERA, PIII, and OPGN HeadlinesRecent News About These CompaniesSera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $32,950.06 in StockJune 12, 2025 | insidertrades.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells 23,042 Shares of StockJune 11, 2025 | marketbeat.comWe Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth CarefullyJune 10, 2025 | finance.yahoo.comSera Prognostics (NASDAQ:SERA) Cut to Sell at Wall Street ZenJune 9, 2025 | americanbankingnews.comsera prognostics announces board elections and auditor ratificationJune 7, 2025 | investing.comSera Prognostics (NASDAQ:SERA) Rating Lowered to "Sell" at Wall Street ZenJune 7, 2025 | marketbeat.comAfter Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)May 29, 2025 | zacks.comSERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESMay 29, 2025 | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial ResultsMay 26, 2025 | finanznachrichten.deSERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCEMay 14, 2025 | prnewswire.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comDown -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a TurnaroundMay 13, 2025 | zacks.comSera Prognostics Inc (SERA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in StockMay 10, 2025 | insidertrades.comSera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial OfficerMay 9, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics reports Q1 2025 earnings beatMay 9, 2025 | investing.comSera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization ProgressesMay 9, 2025 | 360dx.comWhat I Wish I Knew: The Truth About Preterm Birth for Black WomenMay 9, 2025 | blackdoctor.orgSERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICERMay 8, 2025 | prnewswire.comSera Prognostics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comSera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMD, SERA, PIII, and OPGN Company DescriptionsOpGen NASDAQ:OPGN$4.90 -0.04 (-0.81%) As of 02:25 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$6.47 -0.21 (-3.13%) Closing price 03:58 PM EasternExtended Trading$6.47 0.00 (-0.02%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Psychemedics NASDAQ:PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas.Sera Prognostics NASDAQ:SERA$1.78 +0.07 (+4.09%) Closing price 03:58 PM EasternExtended Trading$1.78 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? 3 Stocks With Rising Dividends Investors Shouldn’t Ignore SoundHound’s AI Growth Story Is Just Getting Started MarketBeat Week in Review – 06/09 - 06/13 2 Reasons Adobe Stock Is Ready to Rally This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
